News & Events

Tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy in 1L non-squamous metastatic NSCLC with STK11, KEAP1 and/or KRAS mutations: Interim analysis of the phase 2b TRITON study

Tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy in 1L non-squamous metastatic NSCLC with STK11, KEAP1 and/or KRAS mutations: Interim analysis of the phase 2b TRITON study

Findings from Fudan University Has Provided New Information about Non-Small Cell Lung Cancer (Oncogenic KRAS Represses the Dependence Receptor UNC5C via ERK2-FOS Signaling in Non-Small...

Findings from Fudan University Has Provided New Information about Non-Small Cell Lung Cancer (Oncogenic KRAS Represses the Dependence Receptor UNC5C via ERK2-FOS Signaling in Non-Small...

Clinical Trial: SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

Clinical Trial: SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

Beyond KRAS: Using Co-Mutation Status to Guide Immunotherapy Selection in Advanced NSCLC

Beyond KRAS: Using Co-Mutation Status to Guide Immunotherapy Selection in Advanced NSCLC

VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors

VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors

U.S. Clinical Trial: Second Affiliated Hospital, School of Medicine, Zhejiang University Listed a New Clinical Trial to Study SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant...

U.S. Clinical Trial: Second Affiliated Hospital, School of Medicine, Zhejiang University Listed a New Clinical Trial to Study SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant...

Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer

Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer

New Cancer Therapy Combines KRAS Inhibitors with Metabolic Targeting to Prevent Relapse

New Cancer Therapy Combines KRAS Inhibitors with Metabolic Targeting to Prevent Relapse

Findings on Clinical Oncology Detailed by Rafael Rosell and Co-Authors (Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies)

Findings on Clinical Oncology Detailed by Rafael Rosell and Co-Authors (Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies)

New Findings from Sichuan Cancer Hospital Describe Advances in Brain Metastasis (Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with...

New Findings from Sichuan Cancer Hospital Describe Advances in Brain Metastasis (Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with...